Abiraterone acetate tablets

DRUG6 trials

Conditions

Abiraterone AcetateAdvanced Prostate CancerGene PolymorphismHealthy VolunteersHormone Sensitive Prostate CancerMetabolic AnalysisMetastatic Castration-resistant Prostate CancerMetastatic Tumor

Early Phase 1

Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults

NCT04735913

Zhongnan HospitalAbiraterone Acetate, Gene Polymorphism, Metabolic Analysis +2

Start: 2020-05-05End: 2022-07-01Target: 81Updated: 2022-01-03

Phase 1

A Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation in Healthy Adult Volunteers

CompletedNCT01362764

Cougar Biotechnology, Inc.Healthy Volunteers

Start: 2011-05-31End: 2011-06-30Updated: 2012-11-27

To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

TerminatedNCT05405439

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Metastatic Castration-resistant Prostate Cancer

Start: 2022-08-25End: 2023-07-19Updated: 2023-11-03

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

RecruitingNCT05942001

Jiangsu HengRui Medicine Co., Ltd.Advanced Prostate Cancer

Start: 2023-08-03End: 2026-09-01Target: 100Updated: 2026-08-31

Phase 2

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

TerminatedNCT05588609

Partner Therapeutics, Inc.Metastatic Castration-resistant Prostate Cancer, NSCLC Harboring NRG1 Fusion

Start: 2022-11-17End: 2025-07-03Updated: 2026-04-27

Unknown Phase

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

RecruitingNCT06473259

Santa Chiara HospitalHormone Sensitive Prostate Cancer, Metastatic Tumor, Prostate Cancer

Start: 2016-12-16End: 2028-12-31Target: 3000Updated: 2024-06-25

Related Papers

HRS-5041, an androgen receptor degrader, in metastatic castration-resistant prostate cancer: A phase 1, multicenter, first-in-human study.

Journal of Clinical Oncology2026-05-27